Market Cap 27.49B
Revenue (ttm) 4.66B
Net Income (ttm) 836.30M
EPS (ttm) N/A
PE Ratio 29.55
Forward PE 26.74
Profit Margin 17.94%
Debt to Equity Ratio 0.42
Volume 3,299,200
Avg Vol 5,947,396
Day's Range N/A - N/A
Shares Out 385.87M
Stochastic %K 86%
Beta 1.45
Analysts Strong Sell
Price Target $83.65

Company Profile

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with predi...

Industry: Medical Devices
Sector: Healthcare
Phone: 858 200 0200
Address:
6340 Sequence Drive, San Diego, United States
StreakGeek
StreakGeek Jul. 2 at 5:44 PM
0 · Reply
JackDarwin
JackDarwin Jul. 2 at 1:23 PM
$DXCM Bullish Harami Candlestick Pattern Formed at Downtrend
0 · Reply
Punpire
Punpire Jul. 1 at 8:15 PM
$SENS Using the Eversense 365 compared to the $DXCM G7 feels like this Add for Black Rifle Coffee Company. Senseonics needs to hire who ever the Marketing person is for Black Rifle. https://youtu.be/PTHoW447564
0 · Reply
purdiestpam
purdiestpam Jul. 1 at 2:34 PM
$DXCM can’t wait till 100
0 · Reply
professional_quicker
professional_quicker Jun. 30 at 7:49 PM
$DXCM +67% RETURN Profit secured. 🎯
0 · Reply
Cutlass
Cutlass Jun. 30 at 7:38 PM
$DXCM As always, load zone 55 - 60 🤠
0 · Reply
SPY_PRIM
SPY_PRIM Jun. 30 at 7:35 PM
$DXCM DXCM 67%
0 · Reply
Chrissytina
Chrissytina Jun. 30 at 2:56 PM
$DXCM Good news & target prices around the $85 range with a buy signal. 🤦🏼‍♀️ So, why the sell off 2 days now.
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Jun. 30 at 1:08 PM
🧬 $MODD : A Major Milestone Just Arrived. Is This Only the Beginning? 📈 Modular Medical develops innovative tubeless insulin patch pumps designed to simplify insulin therapy for people with diabetes Today, the company announced that the first patients are now actively using its Pivot system, marking a major milestone in its commercial launch 🔹 First patients are now actively using the Pivot pump following physician training 🔹 Pivot starter kits recently began shipping to endocrinology practices across the U.S. 🔹 Received FDA clearance earlier this year, enabling commercial launch 🔹 Pivot is designed for the millions of insulin dependent adults still relying on multiple daily injections 🔹 Trading within the $4.90–$6.02 consolidation range 🔹 $6.02 is the key breakout level to watch 🔹 A break above $6.02 could open the door toward $7.83+, with $13.67–$14.74 as major resistance Communicated Disclaimer: https://stockresearchtoday.com/modd/ Sector Peers:$PODD $DXCM $TNDM $SENS
0 · Reply
AXLFI_HQ
AXLFI_HQ Jun. 30 at 1:08 PM
$DXCM FDA regulatory approvals are expanding for healthcare innovations including novel antibiotics, immunotherapies, and precision diagnostics, creating new market opportunities and growth drivers for medical device and pharmaceutical companies. Learn more: https://axlfi.com/themes/357
0 · Reply
Latest News on DXCM
DexCom initiated with a Buy at Deutsche Bank

2026-06-23T16:59:55.000Z - 11 days ago

DexCom initiated with a Buy at Deutsche Bank


DexCom initiated with a Buy at Deutsche Bank

2026-06-23T13:19:58.000Z - 11 days ago

DexCom initiated with a Buy at Deutsche Bank


Dexcom Further Advances Vision of Glucose Biosensing for All

Jun 23, 2026, 9:00 AM EDT - 11 days ago

Dexcom Further Advances Vision of Glucose Biosensing for All


The Healthcare M&A Wave

Jun 17, 2026, 12:30 PM EDT - 17 days ago

The Healthcare M&A Wave

ABT ALNY AMGN AMRX ANTX AZN BDX


DexCom price target raised to $88 from $75 at Piper Sandler

2026-06-15T10:42:11.000Z - 19 days ago

DexCom price target raised to $88 from $75 at Piper Sandler


FDA clears first over-the-counter glucose monitor for children

Jun 12, 2026, 4:15 PM EDT - 22 days ago

FDA clears first over-the-counter glucose monitor for children


DexCom price target raised to $95 from $75 at TD Cowen

2026-06-10T12:28:14.000Z - 24 days ago

DexCom price target raised to $95 from $75 at TD Cowen


DexCom price target raised to $85 from $75 at Mizuho

2026-06-09T11:10:24.000Z - 25 days ago

DexCom price target raised to $85 from $75 at Mizuho


DexCom price target raised to $91 from $81 at Raymond James

2026-06-08T19:20:09.000Z - 26 days ago

DexCom price target raised to $91 from $81 at Raymond James


DexCom announces results from CONNECT trial of Dexcom G7

2026-06-07T22:00:07.000Z - 27 days ago

DexCom announces results from CONNECT trial of Dexcom G7


DexCom price target raised to $90 from $85 at Stifel

2026-06-05T11:09:50.000Z - 4 weeks ago

DexCom price target raised to $90 from $85 at Stifel


DexCom price target raised to $84 from $79 at Citi

2026-05-28T12:20:33.000Z - 5 weeks ago

DexCom price target raised to $84 from $79 at Citi


DexCom identifies theft of scrapped Dexcom G7 sensors

2026-05-26T16:46:26.000Z - 5 weeks ago

DexCom identifies theft of scrapped Dexcom G7 sensors


Dexcom warns patients as stolen glucose sensors hit the market

May 26, 2026, 10:47 AM EDT - 5 weeks ago

Dexcom warns patients as stolen glucose sensors hit the market


DexCom announces Dexcom Flex in Germany

2026-05-18T11:48:09.000Z - 6 weeks ago

DexCom announces Dexcom Flex in Germany


DexCom price target lowered to $80 from $100 at BofA

2026-05-18T11:28:09.000Z - 6 weeks ago

DexCom price target lowered to $80 from $100 at BofA


DexCom price target lowered to $82 from $100 at Canaccord

2026-05-18T11:10:49.000Z - 6 weeks ago

DexCom price target lowered to $82 from $100 at Canaccord


DexCom price target lowered to $64 from $67 at Barclays

2026-05-18T09:46:16.000Z - 6 weeks ago

DexCom price target lowered to $64 from $67 at Barclays


DexCom Transcript: Investor Day 2026

May 14, 2026, 4:15 PM EDT - 7 weeks ago

DexCom Transcript: Investor Day 2026


DexCom Slides: FY 2026

May 14, 2026, 4:15 PM EDT - 7 weeks ago

DexCom Slides: FY 2026


Dexcom to Host Investor Day on May 14, 2026

May 5, 2026, 8:30 AM EDT - 2 months ago

Dexcom to Host Investor Day on May 14, 2026


DexCom Earnings Call Transcript: Q1 2026

Apr 30, 2026, 4:30 PM EDT - 2 months ago

DexCom Earnings Call Transcript: Q1 2026


DexCom Earnings release: Q1 2026

Apr 30, 2026, 4:30 PM EDT - 2 months ago

DexCom Earnings release: Q1 2026


DexCom Slides: Q1 2026

Apr 30, 2026, 4:30 PM EDT - 2 months ago

DexCom Slides: Q1 2026


DexCom Quarterly report: Q1 2026

Apr 30, 2026, 4:30 PM EDT - 2 months ago

DexCom Quarterly report: Q1 2026


Dexcom Reports First Quarter 2026 Financial Results

Apr 30, 2026, 4:02 PM EDT - 2 months ago

Dexcom Reports First Quarter 2026 Financial Results


DexCom Slides: Investor presentation

Apr 30, 2026, 7:00 AM EDT - 2 months ago

DexCom Slides: Investor presentation


DexCom Proxy statement: Proxy filing

Apr 15, 2026, 8:00 AM EDT - 2 months ago

DexCom Proxy statement: Proxy filing


DexCom Proxy statement: Proxy filing

Apr 15, 2026, 8:00 AM EDT - 2 months ago

DexCom Proxy statement: Proxy filing


Dexcom Appoints Rick Osterloh to Board of Directors

Feb 26, 2026, 4:15 PM EST - 4 months ago

Dexcom Appoints Rick Osterloh to Board of Directors


Dexcom Announces Upcoming Conference Presentation

Feb 25, 2026, 8:30 AM EST - 4 months ago

Dexcom Announces Upcoming Conference Presentation


The Big 3: VZ, DXCM, AMAT

Feb 19, 2026, 1:00 PM EST - 4 months ago

The Big 3: VZ, DXCM, AMAT

AMAT VZ


DexCom Earnings Call Transcript: Q4 2025

Feb 12, 2026, 4:30 PM EST - 5 months ago

DexCom Earnings Call Transcript: Q4 2025


DexCom Annual report: Q4 2025

Feb 12, 2026, 4:30 PM EST - 5 months ago

DexCom Annual report: Q4 2025


DexCom Earnings release: Q4 2025

Feb 12, 2026, 4:30 PM EST - 5 months ago

DexCom Earnings release: Q4 2025


DexCom Slides: Q4 2025

Feb 12, 2026, 4:30 PM EST - 5 months ago

DexCom Slides: Q4 2025


DexCom Slides: Investor presentation

Feb 12, 2026, 7:00 AM EST - 5 months ago

DexCom Slides: Investor presentation


Watch CNBC's exclusive interview with Dexcom CEO Jake Leach

Jan 13, 2026, 5:24 PM EST - 6 months ago

Watch CNBC's exclusive interview with Dexcom CEO Jake Leach


DexCom Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 10:30 AM EST - 6 months ago

DexCom Transcript: 44th Annual J.P. Morgan Healthcare Conference


DexCom Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 10:30 AM EST - 6 months ago

DexCom Slides: 44th Annual J.P. Morgan Healthcare Conference


StreakGeek
StreakGeek Jul. 2 at 5:44 PM
0 · Reply
JackDarwin
JackDarwin Jul. 2 at 1:23 PM
$DXCM Bullish Harami Candlestick Pattern Formed at Downtrend
0 · Reply
Punpire
Punpire Jul. 1 at 8:15 PM
$SENS Using the Eversense 365 compared to the $DXCM G7 feels like this Add for Black Rifle Coffee Company. Senseonics needs to hire who ever the Marketing person is for Black Rifle. https://youtu.be/PTHoW447564
0 · Reply
purdiestpam
purdiestpam Jul. 1 at 2:34 PM
$DXCM can’t wait till 100
0 · Reply
professional_quicker
professional_quicker Jun. 30 at 7:49 PM
$DXCM +67% RETURN Profit secured. 🎯
0 · Reply
Cutlass
Cutlass Jun. 30 at 7:38 PM
$DXCM As always, load zone 55 - 60 🤠
0 · Reply
SPY_PRIM
SPY_PRIM Jun. 30 at 7:35 PM
$DXCM DXCM 67%
0 · Reply
Chrissytina
Chrissytina Jun. 30 at 2:56 PM
$DXCM Good news & target prices around the $85 range with a buy signal. 🤦🏼‍♀️ So, why the sell off 2 days now.
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Jun. 30 at 1:08 PM
🧬 $MODD : A Major Milestone Just Arrived. Is This Only the Beginning? 📈 Modular Medical develops innovative tubeless insulin patch pumps designed to simplify insulin therapy for people with diabetes Today, the company announced that the first patients are now actively using its Pivot system, marking a major milestone in its commercial launch 🔹 First patients are now actively using the Pivot pump following physician training 🔹 Pivot starter kits recently began shipping to endocrinology practices across the U.S. 🔹 Received FDA clearance earlier this year, enabling commercial launch 🔹 Pivot is designed for the millions of insulin dependent adults still relying on multiple daily injections 🔹 Trading within the $4.90–$6.02 consolidation range 🔹 $6.02 is the key breakout level to watch 🔹 A break above $6.02 could open the door toward $7.83+, with $13.67–$14.74 as major resistance Communicated Disclaimer: https://stockresearchtoday.com/modd/ Sector Peers:$PODD $DXCM $TNDM $SENS
0 · Reply
AXLFI_HQ
AXLFI_HQ Jun. 30 at 1:08 PM
$DXCM FDA regulatory approvals are expanding for healthcare innovations including novel antibiotics, immunotherapies, and precision diagnostics, creating new market opportunities and growth drivers for medical device and pharmaceutical companies. Learn more: https://axlfi.com/themes/357
0 · Reply
CmonManGiveMeABreak
CmonManGiveMeABreak Jun. 29 at 11:12 PM
$DXCM helps to find out your glucose levels
0 · Reply
SPY_PRIM
SPY_PRIM Jun. 29 at 7:54 PM
$DXCM 40%
0 · Reply
thomos
thomos Jun. 29 at 7:29 PM
$DXCM 07/10 | 69 PUT Entry: $1.39 📉🔥
0 · Reply
professional_quicker
professional_quicker Jun. 29 at 6:51 PM
$DXCM 0710 69P 1.39
0 · Reply
SPY_PRIM
SPY_PRIM Jun. 29 at 6:43 PM
HIGH CONFIDENCE $DXCM 0710 69p $1.39
0 · Reply
Punpire
Punpire Jun. 29 at 4:47 PM
$DXCM Feels like this once great and dependable stock is going to be forever stuck at these levels. It has seen it's best days and those days won't return I'm afraid. Dexcom dominated for years when they were the only CGM on the market but with better products today like the Eversense 365 and the utter failure of the G7, Diabetics are fleeing as fast as they can. $SENS also feels stuck at it's current level but they have a product that only needs better management and a competent CEO.
1 · Reply
BioTechHealthX
BioTechHealthX Jun. 28 at 7:12 AM
$DXCM DexCom Inc. (DXCM) is pushing glucose monitoring beyond traditional diabetes care, using biosensors, wearable health data, and smarter digital insights to target a much bigger healthcare market. https://biotechhealthx.com/biotech-news/could-dexcom-dxcm-be-a-smart-long-term-buy-in-medical-devices/
0 · Reply
BioTechHealthX
BioTechHealthX Jun. 28 at 6:10 AM
$DXCM $GEHC $INSM $NTRA $VEEV From obesity drugs and genetic testing to glucose biosensors, cloud imaging, and surgical tools, these 10 AI healthcare stocks show how artificial intelligence is reshaping patient care, diagnostics, drug research, and medical technology. https://biotechhealthx.com/biotech-news/top-10-ai-powered-healthcare-stocks-that-can-make-you-rich/
0 · Reply
CmonManGiveMeABreak
CmonManGiveMeABreak Jun. 26 at 10:17 PM
$DXCM Glucose is vital. It fuels your body and your brain. Understanding and managing it is essential for those with diabetes and beneficial for everyone’s health.
0 · Reply
purdiestpam
purdiestpam Jun. 26 at 8:14 PM
$DXCM big on dexcom calls dec expiration
0 · Reply
AXLFI_HQ
AXLFI_HQ Jun. 26 at 12:28 PM
$DXCM FDA regulatory approvals are expanding for healthcare innovations including novel antibiotics, immunotherapies, and precision diagnostics, creating new market opportunities and growth drivers for medical device and pharmaceutical companies. Learn more: https://axlfi.com/themes/357
0 · Reply
BillionerOfKing
BillionerOfKing Jun. 25 at 10:45 PM
$DXCM Current Stock Price: $68.64 Contracts to trade: $69.0 DXCM Jun 26 2026 Call Entry: $1.62 Exit: $2.87 ROI: 77% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply